Research and Markets (http://www.researchandmarkets.com/research/b168ba/france_pharmaceuti) has announced the addition of the "France Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
This France Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on France's pharmaceuticals and healthcare industry.
In this Business Environment Rankings (BER) for Q409, France remains ranked 3rd out of the 9 Western European markets surveyed. Despite its unwavering focus on cost-containment, the country's position in the regional market has improved since Q209, buoyed by high per capita spending on drugs and the tradition of high prescribing and usage of medicines. Additionally, France benefits from a strong emphasis on its regulatory environment, although foreign companies have been critical of the country's 'aggressive' promotion of generics. However, as the French economy is suffering along with the rest of the eurozone, and as a recovery will have to wait until well into 2010, the government is unlikely to relinquish its grip on public healthcare expenditure.
Overall, the publisher calculates that France's pharmaceutical expenditure will rise from some EUR34.07bn (US$50.10bn) in 2008 to EUR38.81bn (US$49.12bn) in 2013. This equates to a compound annual growth rate (CAGR) of 2.64% in euro terms, although the market value in US dollar terms will suffer from the weakening of the euro in the current year. Generic and over-the-counter (OTC) drugs are expected to perform better than the patented segment, which will continue to be the target of cost-containment. Generics especially are expected to post a healthy 12.75% CAGR in local currency terms, accounting for 14% of the total market value in 2013.